Encompass Health Co. (NYSE:EHC) Shares Acquired by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Encompass Health Co. (NYSE:EHC) by 0.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 769,716 shares of the company’s stock after purchasing an additional 2,904 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.76% of Encompass Health worth $71,083,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EHC. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Encompass Health by 87.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock worth $27,000 after acquiring an additional 137 shares during the last quarter. UMB Bank n.a. lifted its holdings in Encompass Health by 387.7% in the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company’s stock valued at $31,000 after purchasing an additional 252 shares in the last quarter. V Square Quantitative Management LLC boosted its stake in shares of Encompass Health by 53.0% during the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock worth $39,000 after purchasing an additional 140 shares during the last quarter. Avior Wealth Management LLC purchased a new stake in shares of Encompass Health during the third quarter worth about $40,000. Finally, Tompkins Financial Corp acquired a new position in shares of Encompass Health in the fourth quarter valued at approximately $46,000. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on EHC. KeyCorp lifted their target price on shares of Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 29th. Royal Bank of Canada upped their target price on Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Barclays raised their price target on Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday. StockNews.com downgraded shares of Encompass Health from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Truist Financial reissued a “buy” rating and issued a $116.00 target price (up from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Encompass Health has a consensus rating of “Buy” and an average target price of $107.33.

Encompass Health Price Performance

EHC opened at $99.86 on Monday. The company has a 50 day moving average of $96.28 and a two-hundred day moving average of $95.30. Encompass Health Co. has a 52-week low of $72.37 and a 52-week high of $104.55. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The company has a market cap of $10.06 billion, a P/E ratio of 22.39, a P/E/G ratio of 1.18 and a beta of 0.90.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 18.06% and a net margin of 8.48%. On average, analysts expect that Encompass Health Co. will post 4.76 earnings per share for the current year.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.